GlobeNewswire Inc.T3·11d ago
MCRB Seres Therapeutics, Inc.
XNAS
1.98
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MCRB
$1.98
—
Key stats
$1.98
- 52-Week Range
- $1.98 – $29.98
- YTD
- -86.93%
- IV Rank (30D)
- 34.35
- Straddle Price
- $0.68
- P/C Vol Ratio
- 0.07
- Market Cap
- $0.0B
- Open
- $2.11
- Day Range
- $1.98 – $2.19
- Volume
- 53,065
- Prev Close
- $2.09
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 1.07 |
| Cost of Equity (CAPM) | 11.01% (VRP-adj) |
| WACC | 11.01% |
| Volatility Risk Premium | +194.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -65.0% |
| Book / Price | 178.8% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -2724.1% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $3.88 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.69 |
| Bollinger Width / SMA20 | 2190.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$4.84
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.0× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.0× · 3 peers |
| Peer P/B | $12.97 | 16% | median 3.5× · 3 peers |
| Peer P/S | $0.85 | 16% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $3.88 | 69% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 66
- List Date
- 2015-06-26
- CIK
- 0001609809
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($1.34) (1 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.serestherapeutics.com
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -5.23% | -5.66% | 1.30% | -19.29% | 0.19% | -1.52% | -5.04% |
| Feb | -23.84% | -3.61% | -8.01% | -0.87% | -8.60% | -42.31% | -14.54% |
| Mar | -0.15% | -3.72% | 10.10% | -37.07% | -6.49% | -1.00% | -6.39% |
| Apr | 1.76% | -35.56% | -18.20% | 29.15% | -28.28% | -16.82% | -11.33% |
| May | 3.73% | -37.63% | 1.64% | -7.41% | -25.79% | -3.81% | -11.54% |
| Jun | 18.13% | 11.00% | -4.39% | -32.98% | 58.71% | 3.27% | 8.96% |
| Jul | -68.58% | 13.22% | -1.84% | 85.60% | 33.21% | -38.86% | 3.79% |
| Aug | -8.82% | 27.54% | -28.57% | -36.46% | 35.38% | -2.39% | -2.22% |
| Sep | 6.10% | 23.70% | -34.44% | 20.78% | -1.43% | -35.33% | -3.44% |
| Oct | -16.02% | 43.13% | -28.84% | -14.72% | -21.46% | -32.42%* | -11.72% |
| Nov | 67.08% | -28.18% | -27.78% | 19.24% | 18.04% | -- | 9.68% |
| Dec | -22.44% | -16.04% | 30.84% | -10.36% | -14.19% | -- | -6.44% |
| Total | -70.27% | -39.78% | -74.79% | -47.61% | 2.29% | -87.88% | -53.01% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.62
SMA 50: $3.83
SMA 200: $7.39
Current: $1.98
EMA 12: $2.39
EMA 26: $2.89
MACD: -0.5036 | Signal: 0.0083
BEARISH
ADX (14): 57.42
STRONG TREND
+DI: 5.50
−DI: 34.76
Momentum Oscillators
RSI (14): 16.63
OVERSOLD
Stoch %K: 6.61
Stoch %D: 6.55
Williams %R: -100.00
Volume & Volatility
BB Upper: $3.38
BB Lower: $1.86
NEUTRAL
OBV: -1,252,882
Vol SMA 20: 77,912
Vol ROC: -2.47%
ATR: $0.24
True Range: $0.21
HV 20: 63.3%
HV 30: 57.6%
HV 60: 66.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is a comprehensive stock analysis report for MCRB:
Executive Summary
Overall assessment: BEARISH (confidence level: 6/10)
Key drivers and primary risks:
- Technical indicators suggest a bearish trend, with MACD indicating a bearish momentum signal.
- Recent news headlines are generally positive, but the options market is pricing in significant volatility.
- Risk metrics show above-average stock volatility.
Investment thesis: MCRB's recent price action suggests a potential correction or consolidation phase. The technical indicators are warning of a bearish trend, while the options market is pricing in high volatility. This combination could lead to increased uncertainty and potential losses for investors.
Recent news sentiment impact: The positive news headlines have had a limited impact on MCRB's stock price, as the recent news sentiment has been relatively neutral.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Downtrend
- Medium-term (1-3 months): Bearish trend continues
- Long-term (3-12 months): Bullish trend prevails
Support/Resistance Levels: Key price levels to monitor: SMA 20 ($4.88), SMA 50 ($5.47), and Bollinger Bands' lower band ($4.10).
Momentum Signals:
- RSI interpretation: Neutral (62.42)
- MACD signal: Bearish momentum
- Bollinger Bands position: Overbought
Volume Analysis: Volume trends suggest a decline in trading activity, with institutional interest remaining relatively low.
News & Sentiment Analysis
Recent Headlines Summary: The past 10 news articles are generally positive, highlighting company achievements and market trends.
Sentiment Assessment: Aggregate news sentiment is neutral (60% positive, 20% negative, 20% neutral).
Catalyst Identification: No upcoming events or announcements that could significantly impact the stock price.
Market Narrative: The recent news headlines have had a limited impact on MCRB's stock price, as the overall market narrative remains uncertain and mixed.
Risk & Volatility Assessment
Risk Interpretation: Beta: 1.13 (above average), indicating higher risk relative to the broader market.
Volatility Regime: Current volatility is above historical levels, with an IV rank of 41.4% and a current IV of 218.8%.
Options Market Signals: IV rank indicates medium-high volatility, while put/call ratios suggest bullish sentiment.
Downside Protection: Support levels are critical to monitor, particularly the SMA 20 ($4.88) and Bollinger Bands' lower band ($4.10).
Market Context & Positioning
Sector Performance: MCRB's sector is performing relatively well, with a positive R-squared interpretation.
Institutional Activity: Volume patterns suggest low institutional interest, which could impact the stock price.
Correlation Analysis: MCRB's correlation with the broader market is relatively high (0.15), indicating potential amplification of market movements.
Relative Valuation: MCRB's relative valuation within its trading range suggests a potential correction or consolidation phase.
Key Levels & Action Items
Critical Price Levels:
- SMA 20 ($4.88)
- Bollinger Bands' lower band ($4.10)
Breakout/Breakdown Levels:
- Upper Bollinger Band ($5.65) - potential sell signal
Time-Sensitive Catalysts: No upcoming events or announcements that could significantly impact the stock price.
Risk Management: Stop-loss levels should be set around $4.88, with position sizing considerations based on risk tolerance and market volatility.
This comprehensive analysis report provides a detailed assessment of MCRB's technical indicators, news sentiment, risk metrics, and options activity. The overall assessment is bearish due to the technical signals and high volatility, but there are potential risks and opportunities to monitor.
Generated
News
All MCRB news →
GlobeNewswire Inc.T3·1mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·8mo ago
The Motley FoolT3·11mo ago
GlobeNewswire Inc.T3·17mo ago
GlobeNewswire Inc.T3·17mo ago
GlobeNewswire Inc.T3·19mo ago
GlobeNewswire Inc.T3·20mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
18 of 22 under expected move
Avg Expected Move
46.24%
Avg Actual Move
7.52%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-02 | After-Close | 23.31% | 9.99% | 0.43x | Within |
| 2021-05-04 | After-Close | 0.98% | 1.68% | 1.71x | Exceeded |
| 2021-08-03 | After-Close | 16.95% | 1.87% | 0.11x | Within |
| 2021-11-10 | After-Close | 17.82% | 8.34% | 0.47x | Within |
| 2022-03-01 | After-Close | 48.38% | 0.34% | 0.01x | Within |
| 2022-05-04 | After-Close | 0.82% | 7.84% | 9.56x | Exceeded |
| 2023-03-07 | After-Close | 2.78% | 10.00% | 3.60x | Exceeded |
| 2023-04-27 | After-Close | 18.32% | 8.36% | 0.46x | Within |
| 2023-08-08 | After-Close | 29.00% | 6.06% | 0.21x | Within |
| 2023-11-02 | After-Close | 13.40% | 39.43% | 2.94x | Exceeded |
| 2024-01-10 | After-Close | 28.00% | 3.31% | 0.12x | Within |
| 2024-03-05 | After-Close | 16.67% | 4.72% | 0.28x | Within |
| 2024-08-13 | After-Close | 23.95% | 9.07% | 0.38x | Within |
| 2024-11-13 | After-Close | 97.46% | 0.32% | 0.00x | Within |
| 2025-01-10 | After-Close | 82.90% | 2.51% | 0.03x | Within |
| 2025-03-13 | Pre-Market | 336.67% | 7.91% | 0.02x | Within |
| 2025-05-07 | After-Close | 94.69% | 16.10% | 0.17x | Within |
| 2025-08-06 | Pre-Market | 18.73% | 3.47% | 0.19x | Within |
| 2025-11-05 | After-Close | 41.54% | 9.13% | 0.22x | Within |
| 2026-03-12 | After-Close | 32.87% | 4.64% | 0.14x | Within |
| 2026-05-06 | Pre-Market | 41.67% | 6.67% | 0.16x | Within |
| 2026-08-05 | After-Close | 30.47% | 3.70% | 0.12x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MCRB Options Activity & IV Rank
MCRB IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 159.5%
7-DTE IV: —
Expected Move: $0.68
7-DTE Move: $0.68
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 101
Put Volume: 7
P/C Volume: 0.069
BULLISH
Call OI: 432
Put OI: 209
P/C OI: 0.484
Total OI: 641
ATM Options Pricing
ATM Call: $0.38
ATM Put: $0.30
Call %: 18.9%
Put %: 15.2%
Chain Summary
Chain Volume: 555
Chain OI: 4,659
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 10th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
10%
vs own history
GEX tilt
+0.21
OI-weighted, today
Vanna tilt
-0.03
δ-sensitivity to IV
Charm tilt
-0.91
δ-decay vs time
Charm tilt -0.91: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 339.7% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)34.4MediumOct 26
Straddle Price (30 DTE)$0.68Oct 26
Beta Analysis
Risk Metrics
Beta: 1.3647
Alpha: -193.83%
Correlation: 0.1931
R-Squared: 3.7%
Stock Volatility: 90.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MCRB
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $83K | #5860 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MCRB Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 9,242,733 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$608.53K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | HAP TRADING, LLC | $334.75K | 55.01% | 2025-09-30 |
| 2 | Simplex Trading, LLC Custodian | $130.97K | 21.52% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $87.58K | 14.39% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $55.23K | 9.08% | 2026-06-30 |
4 filers$1.06M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $503.38K | 47.40% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $343.21K | 32.32% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $160.96K | 15.16% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $54.44K | 5.13% | 2026-06-30 |
MCRB Insider Trading (Form 4)
Latest: 2026-08-18Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Eric D. Shaff | Director | Mixed | +459 | $4.55 | -$1.2K | EDGAR |
| 2026-08-18 | Matthew R Henn | See Remarks | Mixed | +157 | $4.55 | -$369 | EDGAR |
| 2026-08-18 | Kelly Brady | See Remarks | Mixed | +117 | $4.55 | -$291 | EDGAR |
| 2026-08-18 | Thomas DesRosier | See Remarks | Mixed | +163 | $4.55 | -$373 | EDGAR |
| 2026-07-10 | Eric D. Shaff | Director | Grant (A) | +6,500 opt | — | EDGAR | |
| 2026-07-10 | Thomas DesRosier | See Remarks | Grant (A) | +7,500 opt | — | EDGAR | |
| 2026-07-10 | Matthew R Henn | See Remarks | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-07-10 | Richard N Kender | See Remarks | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-07-10 | Stephen Berenson | Director | Grant (A) | +6,500 opt | — | EDGAR | |
| 2026-07-10 | Robert L. Rosiello | Director | Grant (A) | +6,500 opt | — | EDGAR | |
| 2026-07-10 | Kurt Graves | Director | Grant (A) | +6,500 opt | — | EDGAR | |
| 2026-07-10 | Willard H Dere | Director | Grant (A) | +6,500 opt | — | EDGAR | |
| 2026-07-10 | Marella Thorell | See Remarks | Grant (A) | +7,500 opt | — | EDGAR | |
| 2026-07-10 | Claire Fraser | Director | Grant (A) | +6,500 opt | — | EDGAR | |
| 2026-07-10 | Dennis A Ausiello | Director | Grant (A) | +6,500 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MCRB Insider Holdings
10 insiders · @ $1.98
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Eric D. Shaff | Director | 12,762 | $25.3K | -$914.4K | 31 | 2026-08-18 |
| 2 | Kelly Brady | See Remarks | 8,679 | $17.2K | -$735 | 4 | 2026-08-18 |
| 3 | Teresa L. Young | See Remarks | 8,632 | $17.1K | -$60.6K | 18 | 2026-02-18 |
| 4 | Thomas DesRosier | See Remarks | 8,117 | $16.1K | -$92.8K | 26 | 2026-08-18 |
| 5 | Matthew R Henn | See Remarks | 8,076 | $16.0K | -$2.53M | 26 | 2026-08-18 |
| 6 | Richard N Kender | See Remarks | 3,175 | $6.3K | $0 | 15 | 2026-07-10 |
| 7 | Paul Biondi | Director | 2,381 | $4.7K | $0 | 8 | 2025-04-11 |
| 8 | Lisa von Moltke | See Remarks | 2,215 | $4.4K | -$19.3K | 12 | 2025-02-19 |
| 9 | Willard H Dere | Director | 1,587 | $3.1K | $0 | 11 | 2026-07-10 |
| 10 | Stephen Berenson | Director | 179 | $354 | $0 | 12 | 2026-07-10 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MCRB Board & Officers
As of SEC filings through Aug 18, 2026Directors 8
- Dennis A Ausiello · since Jun 25, 2015
- Richard N Kender · since Jun 25, 2015
- Kurt Graves · since Nov 9, 2015
- Willard H Dere · since Jul 7, 2017
- Stephen Berenson · since Aug 5, 2019
- Eric D. Shaff · listed since Feb 2021
- Claire Fraser · since Jan 4, 2023
- Robert L. Rosiello · since Aug 5, 2025
Officers 6
- Richard N Kender · Interim Chief Executive Officer · listed since Mar 2026
- Matthew R Henn · President and Chief Scientific Officer · listed since Jul 2026
- Marella Thorell · EVP and Chief Financial Officer · since Mar 25, 2024
- Kelly Brady · Chief Operating Officer, EVP · since Mar 2, 2026
- Teresa L. Young · EVP, Chief Commercial & Strategy Officer · listed since Feb 2021
- Thomas DesRosier · EVP and Chief Legal Officer · listed since Mar 2026
Changes in the last 10 years (41)
| Jul 10, 2026 | Matthew R Henn listed as President and Chief Scientific Officer (previously Chief Scientific Officer and EVP) in SEC filings |
| May 30, 2026 | The company announced the departure of Hans-Juergen Woerle from the board in an SEC filing |
| Mar 6, 2026 | Thomas DesRosier listed as EVP and Chief Legal Officer (previously Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President) in SEC filings |
| Mar 6, 2026 | Richard N Kender first listed as Interim Chief Executive Officer in an SEC filing |
| Mar 2, 2026 | Kelly Brady became Chief Operating Officer, EVP |
| Aug 19, 2025 | Thomas DesRosier listed as Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President (previously Chief Legal Officer and EVP) in SEC filings |
| Aug 5, 2025 | Robert L. Rosiello became a director |
| Jul 17, 2025 | The company announced the departure of Eric D. Shaff as CEO and President in an SEC filing |
| Feb 22, 2025 | The company announced the departure of Lisa von Moltke as Executive Vice President and Chief Medical Officer in an SEC filing |
| Feb 4, 2025 | Hans-Juergen Woerle became a director |
| Sep 30, 2024 | Societe des Produits Nestle S.A. became a 10% owner |
| Mar 25, 2024 | Marella Thorell became EVP and Chief Financial Officer |
| Feb 24, 2024 | The company announced the departure of David Arkowitz as Chief Financial Officer in an SEC filing |
| Oct 2, 2023 | The company announced the departure of Gregory Behar from the board in an SEC filing |
| Jan 4, 2023 | Claire Fraser became a director |
| Jul 5, 2022 | Flagship Pioneering Fund VII, L.P. became a 10% owner |
| Jul 5, 2022 | Flagship Pioneering Fund VII General Partner LLC became a 10% owner |
| Feb 7, 2022 | Paula Cloghessy became Executive Vice President, Chief People Officer |
| Jun 1, 2021 | David Arkowitz became Chief Financial Officer |
| Feb 8, 2021 | Teresa L. Young listed as EVP, Chief Commercial & Strategy Officer (previously Chief Commercial & Strategy Officer) in SEC filings |
| Feb 8, 2021 | Eric D. Shaff listed as CEO and President (previously CFO and EVP) in SEC filings |
| Feb 8, 2021 | Eric D. Shaff first listed as a director in an SEC filing |
| Nov 25, 2020 | Noubar Afeyan no longer listed as a director in SEC filings |
| Oct 19, 2020 | David S. Ege became Executive Vice President and Chief Technology Officer |
| Jun 29, 2020 | Teresa L. Young became Chief Commercial & Strategy Officer |
| Apr 24, 2020 | Marcus Chapman listed as SVP, Principal Financial and Accounting Officer (previously Principal Financial and Accounting Officer) in SEC filings |
| Apr 6, 2020 | Lisa von Moltke became Executive Vice President and Chief Medical Officer |
| Mar 20, 2020 | Paul Biondi became a director |
| Jan 28, 2020 | Matthew R Henn listed as Chief Scientific Officer and EVP (previously Chief Scientific Officer) in SEC filings |
| Aug 5, 2019 | Stephen Berenson became a director |
| Jun 18, 2019 | Nutritional Health LTP Fund, L.P. became a 10% owner |
| Jun 18, 2019 | Nutritional Health LTP Fund General Partner LLC became a 10% owner |
| Jun 18, 2019 | Flagship Pioneering Inc. became a 10% owner |
| Jun 18, 2019 | Flagship Pioneering Fund VI, L.P. became a 10% owner |
| Jun 18, 2019 | Flagship Pioneering Fund VI General Partner LLC became a 10% owner |
| Apr 18, 2019 | Marcus Chapman became Principal Financial and Accounting Officer |
| Feb 1, 2019 | Matthew R Henn became Chief Scientific Officer |
| Oct 22, 2018 | Kevin Horgan became Chief Medical Officer and EVP |
| Aug 30, 2018 | Meryl Zausner became a director |
| Jan 30, 2018 | David N Cook listed as Chief Scientific Officer and EVP of R&D (previously Chief Scientific Officer & EVP) in SEC filings |
| Jul 7, 2017 | Willard H Dere became a director |
Not reported recently (25)
- Paul Biondi · Last reported as a director in an SEC filing dated Apr 11, 2025
- Nestle Sa · Last reported as a 10% owner in an SEC filing dated Oct 2, 2024
- Societe des Produits Nestle S.A. · Last reported as a 10% owner in an SEC filing dated Oct 2, 2024
- David S. Ege · Last reported as Executive Vice President and Chief Technology Officer in an SEC filing dated Aug 19, 2024
- Paula Cloghessy · Last reported as Executive Vice President, Chief People Officer in an SEC filing dated Oct 31, 2023
- Noubar Afeyan · Last reported as a 10% owner in an SEC filing dated Jul 7, 2022
- Flagship Pioneering Inc. · Last reported as a 10% owner in an SEC filing dated Jul 7, 2022
- Nutritional Health LTP Fund General Partner LLC · Last reported as a 10% owner in an SEC filing dated Jul 7, 2022
- Nutritional Health LTP Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 7, 2022
- Flagship Pioneering Fund VII, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 7, 2022
- Flagship Pioneering Fund VII General Partner LLC · Last reported as a 10% owner in an SEC filing dated Jul 7, 2022
- Meryl Zausner · Last reported as a director in an SEC filing dated Jul 6, 2022
- Marcus Chapman · Last reported as SVP, Principal Financial and Accounting Officer in an SEC filing dated Feb 8, 2021
- Flagship Ventures Fund IV, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 25, 2020
- Flagship Ventures Fund IV-Rx, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 25, 2020
- Flagship Ventures Fund IV General Partner LLC · Last reported as a 10% owner in an SEC filing dated Nov 25, 2020
- Flagship Pioneering Fund VI General Partner LLC · Last reported as a 10% owner in an SEC filing dated Nov 25, 2020
- Flagship Pioneering Fund VI, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 25, 2020
- John G. Aunins · Last reported as Chief Technology Officer & EVP in an SEC filing dated Jan 31, 2020
- Roger Pomerantz · Last reported as a director in an SEC filing dated Jun 14, 2019
- Lorence H. Kim · Last reported as a director in an SEC filing dated Jun 14, 2019
- David N Cook · Last reported as Chief Scientific Officer and EVP of R&D in an SEC filing dated Jan 29, 2019
- Kevin Horgan · Last reported as Chief Medical Officer and EVP in an SEC filing dated Jan 29, 2019
- Michele Trucksis · Last reported as Chief Medical Officer and EVP in an SEC filing dated Jan 30, 2018
- Wael Hashad · Last reported as EVP & Chief Commercial Officer in an SEC filing dated Jan 27, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MCRB Proposed Insider Sales (Form 144)
Latest: 2026-05-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | TERESA L YOUNG | Officer | 167 | $1.3K | 2026-05-19 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-17 | TERESA L YOUNG | Officer | 8,553 | $78.0K | 2026-03-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
7 ETFs hold MCRB
7 shown · $1.34M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $690,670 | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $254,094 | — | 2026-09-30 |
| 3 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $227,484 | — | 2026-05-31 |
| 4 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.00% | $62,375 | — | 2026-07-31 |
| 5 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.01% | $55,688 | — | 2026-06-30 |
| 6 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.00% | $48,526 | $1.2B | 2026-10-23 |
| 7 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $2,096 | $3.2B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.43
TTM Revenue
$1.88M
TTM Net Income
$-22.46M
TTM Op. Cash Flow
$-51.26M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $736.00K | $4.58M | $0.47 | $-22.39M |
| Q1 '26 | 2026-03-31 | $358.00K | $-19.91M | $-2.08 | $-16.36M |
| Q4 '25 | 2025-12-31 | $438.00K | $-15.34M | $-1.76 | $-14.71M |
| Q3 '25 | 2025-09-30 | $351.00K | $8.20M | $0.94 | $2.21M |
| Q2 '25 | 2025-06-30 | — | $-19.86M | $-2.27 | $-13.29M |
| Q1 '25 | 2025-03-31 | — | $32.68M | $3.75 | $26.91M |
| Q4 '24 | 2024-12-31 | — | $-15.64M | — | $-38.88M |
| Q3 '24 | 2024-09-30 | — | $88.78M | $11.63 | $-34.68M |
| Q2 '24 | 2024-06-30 | — | $-32.87M | $-4.34 | $-39.81M |
| Q1 '24 | 2024-03-31 | — | $-40.13M | $-5.49 | $-35.24M |
| Q4 '23 | 2023-12-31 | $64.00K | $-41.25M | $-6.40 | $-47.50M |
| Q3 '23 | 2023-09-30 | — | $-47.85M | $-7.40 | $-59.26M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.53
P/S
9.72
EV/EBITDA
—
EV/Sales
1.44
ROE
-65.0%
ROA
-22.1%
Div Yield
0.00%
FCF Yield
-280.09%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$18.30M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
314.26K
SI % of Float
4.45%
Days to Cover
5.15
Short Vol Ratio
28.6%
Free Float
7.06M
Float %
71.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-07